Endovalve Inc.
This article was originally published in Start Up
Executive Summary
Large and small device companies alike are flocking to the large, undermet opportunity of mitral valve regurgitation. Most are focused on techniques for repairing damaged valves. Endovalve Inc. is the first to attempt to commercialize a percutaneous approach to replacing damaged mitral valves.
You may also be interested in...
Micro Interventional Devices: Creating A Tool Box For Structural Heart Disease
Micro Interventional Devices was founded around opportunities in addressing the procedural challenges that limit patient access to transcatheter heart valves. The company’s initial focus is on developing a transcatheter valve for the replacement of the mitral valve, and an easy and effective transapical access and closure method for transcatheter mitral and aortic valve procedures. The company’s mission, though, is to broadly focus on advancing structural heart disease treatments, and MID’s first-generation technology has potential application to several areas of structural heart disease, including PFO/atrial septal defect closure, left atrial appendage closure and cardiac ablations.
Percutaneous Mitral Valve Therapy: The Next Decade
After more than a decade, the field of transcatheter mitral valve therapy is still in its infancy, yet it is surprisingly crowded. The first percutaneous mitral valve company was founded in 1999, the same year that the first transcatheter aortic valve implantation (TAVI) company was founded, but while TAVI is now on the market in Europe and in the US, the leading transcatheter mitral valve therapy has only just completed clinical trials.
NeoChord Inc.
NeoChord wants to enable less invasive mitral valve repair with the NeoChord DS1000 is a tool for implanting artificial chordae tendineae made of suturing material while the heart is still beating.